Comparison

Retatrutide vs. VK2735

Two peptides side-by-side — identity, evidence base, legal status and known adverse events.

Identity

Mechanism of action

Retatrutide

Retatrutide is a 39-amino-acid peptide with agonism at three incretin/energy-balance receptors: GLP-1R (insulin secretion, satiety), GIPR (insulin sensitivity, lipid metabolism) and the glucagon receptor (energy expenditure, lipolysis). The added glucagon activation is intended to raise catabolic energy expenditure while concurrent GLP-1/GIP action compensates the hyperglycaemic effect. Albumin binding via a fatty-acid side chain enables weekly dosing.

VK2735

VK2735 activates both the GLP-1 and the GIP receptor — a dual mechanism similar to that of tirzepatide, suppressing appetite and food intake.

Evidence base

Highest evidence

Human RCT

Studies

of which in humans

Effects recorded

Open conflicts

Documented adverse events

Legal status

Country	Retatrutide	VK2735
Germany	Unapproved	Unapproved
JP	Unapproved	—
United States	Unapproved	Unapproved

Full entries

Frequently asked questions

What is the difference between Retatrutide and VK2735?: Retatrutide is classified as "Metabolic", while VK2735 is classified as "Metabolic". Retatrutide: Synthetic triagonist peptide that simultaneously activates the GLP-1, GIP and glucagon receptors. Developed by Eli Lilly; in phase-3 trials for obesity (TRIUMPH programme) and type 2 diabetes. No marketing approval yet. VK2735: VK2735 is a dual GLP-1/GIP receptor agonist from Viking Therapeutics, in development in both subcutaneous and oral forms for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Retatrutide or VK2735?: The highest available evidence level is "Human RCT" for Retatrutide and "Human RCT" for VK2735. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Retatrutide and VK2735 in Germany and the United States?: Germany: Retatrutide — Unapproved, VK2735 — Unapproved. United States: Retatrutide — Unapproved, VK2735 — Unapproved. These are factual summaries with source and review date on the individual pages.

Country

Retatrutide

VK2735

Germany

Unapproved

—

United States

Unapproved

Frequently asked questions

What is the difference between Retatrutide and VK2735?

Retatrutide is classified as "Metabolic", while VK2735 is classified as "Metabolic". Retatrutide: Synthetic triagonist peptide that simultaneously activates the GLP-1, GIP and glucagon receptors. Developed by Eli Lilly; in phase-3 trials for obesity (TRIUMPH programme) and type 2 diabetes. No marketing approval yet. VK2735: VK2735 is a dual GLP-1/GIP receptor agonist from Viking Therapeutics, in development in both subcutaneous and oral forms for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Retatrutide or VK2735?

The highest available evidence level is "Human RCT" for Retatrutide and "Human RCT" for VK2735. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Retatrutide and VK2735 in Germany and the United States?

Germany: Retatrutide — Unapproved, VK2735 — Unapproved. United States: Retatrutide — Unapproved, VK2735 — Unapproved. These are factual summaries with source and review date on the individual pages.